Gout is a common hyperuricaemic metabolic condition that leads to painful inflammatory
arthritis and a high comorbidity burden, especially cardiometabolic-renal (CMR) conditions …

In the last 4 years, several evidence-based, national, and international guidelines on the
management of arterial hypertension have been published, mostly with concordant …

Gout is the most common cause of inflammatory arthritis worldwide. In UK general practice,
the overall prevalence has increased from 1.4% in 1999 to 2.49% in 2012 [1], despite the …

Objective: To develop evidence based recommendations for the management of gout.
Methods: The multidisciplinary guideline development group comprised 19 rheumatologists …

Objective To determine the independent associations of antihypertensive drugs with the risk
of incident gout among people with hypertension. Design Nested case-control study. Setting …

Antihypertensive drug therapy is one of the most efficient medical interventions for
preventing disability and death globally. Most of the evidence supporting its benefits has …

SUMMARY A substantial body of epidemiological and experimental evidence suggests that
serum uric acid is an important, independent risk factor for cardiovascular and renal disease …

Elevated serum uric acid (SUA) levels are commonly seen in patients with the metabolic
syndrome (MetS). Several mechanisms, both direct and indirect, connect the increased SUA …

Aim To evaluate the effect of empagliflozin on uric acid (UA) levels, antigout medication and
gout episodes in the EMPA‐REG OUTCOME trial (NCT01131676). Materials and methods A …

Gout is the most prevalent inflammatory arthritis and affects 2.5% of the general population
in the UK. It is also the only arthritis that has the potential to be cured with safe, inexpensive …